Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis

Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis

Abstract Background The study aimed to compare efficacy and safety of various immune checkpoint inhibitors for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). Methods We searched Medline, Web of Science, Cochrane Central Register of Controlled Trials, Embase, Clinical...

Full description

Bibliographic Details
Main Authors:	Tian-Tian Gao, Jia-Hui Shan, Yu-Xian Yang, Ze-Wei Zhang, Shi-Liang Liu, Mian Xi, Meng-Zhong Liu, Lei Zhao
Format:	Article
Language:	English
Published:	BMC 2022-09-01
Series:	BMC Cancer
Subjects:	Esophageal squamous cell carcinoma Advanced or metastatic Immunotherapy Network meta-analysis
Online Access:	https://doi.org/10.1186/s12885-022-10086-5

Similar Items

Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
by: Ruixi Wang, et al.
Published: (2022-10-01)

Chemoradiotherapy Versus Chemotherapy Alone for Advanced Esophageal Squamous Cell Carcinoma: The Role of Definitive Radiotherapy for Primary Tumor in the Metastatic Setting
by: Li-Qing Li, et al.
Published: (2022-03-01)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
by: Xiaoyue Wu, et al.
Published: (2023-01-01)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
by: Jincheng Wang, et al.
Published: (2022-09-01)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
by: Wenwu He, et al.
Published: (2023-02-01)

Mucin 1 expression correlates with metastatic recurrence in postoperative patients with esophageal squamous cell cancer
by: Zhi-Gang Sun, et al.
Published: (2017-02-01)

Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III–IVA esophageal squamous cell carcinoma post-surgery
by: Chunyang Li, et al.
Published: (2024-01-01)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
by: Shuhui Xu, et al.
Published: (2023-02-01)

Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?
by: Hannah Christina Puhr, et al.
Published: (2021-09-01)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01)

Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: The Current and Future Role of Radiation Therapy in the Era of Immunotherapy
by: Gianluca Ferini, et al.
Published: (2022-04-01)

Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers
by: Adam Barsouk, et al.
Published: (2019-09-01)

Prognostic significance of baseline peripheral blood lymphocyte subsets on second-line immunotherapy in advanced esophageal squamous cell carcinoma
by: Qike Wang, et al.
Published: (2023-08-01)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
by: Jing Huang, et al.
Published: (2021-03-01)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
by: Qing Zhou, et al.
Published: (2023-09-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit
by: Yi Yang, et al.
Published: (2022-07-01)

Single‐Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Esophageal Squamous Cell Carcinoma
by: Yongxu Jia, et al.
Published: (2023-03-01)

Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
by: Jun Wang, et al.
Published: (2022-11-01)

A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer
by: Qianhe Ren, et al.
Published: (2023-05-01)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Christian Borel, et al.
Published: (2020-09-01)

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
by: Zhao J, et al.
Published: (2023-08-01)

Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
by: Yan Li, et al.
Published: (2022-06-01)

Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence
by: Sundaram Subramanian, et al.
Published: (2019-01-01)

Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment
by: Rongyang Li, et al.
Published: (2023-01-01)

Overview of Risk Factors for Esophageal Squamous Cell Carcinoma in China
by: Erica Conway, et al.
Published: (2023-11-01)

Metastatic squamous cell carcinoma of colon from esophageal cancer
by: Natasha Garg, et al.
Published: (2017-04-01)

Esophageal Metastatic Adenocarcinoma Diagnosed with Endoscopic Ultrasound
by: Guo Xiang Jonathan Teh, et al.
Published: (2017-11-01)

Ferroptosis patterns and tumor microenvironment infiltration characterization in esophageal squamous cell cancer
by: Lu-Lu Zhang, et al.
Published: (2022-12-01)

Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers
by: Fahan Ma, et al.
Published: (2024-03-01)

Immunotherapy for Esophageal Cancer: State-of-the Art in 2021
by: Hugo Teixeira Farinha, et al.
Published: (2022-01-01)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Andrea Alberti, et al.
Published: (2022-06-01)

Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
by: Fei Ya Lai, et al.
Published: (2023-10-01)

Unusual Presentation of a Metastatic Esophageal Carcinoma
by: Katarzyna Orlicka, et al.
Published: (2012-05-01)

The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma
by: Dao Xin, et al.
Published: (2023-05-01)

The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab
by: Liu J, et al.
Published: (2022-10-01)

Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial designCentral MessagePerspective
by: Yuyan Zheng, MD, et al.
Published: (2022-03-01)

Eosinophils Exert Antitumorigenic Effects in the Development of Esophageal Squamous Cell CarcinomaSummary
by: Justin Jacobse, et al.
Published: (2023-01-01)

Prognostic Value of Lactate Dehydrogenase in Advanced Esophageal Squamous Cell Carcinoma Patients with Immunotherapy
by: Yan LI, Kunlun WANG, Hui YANG, Erjiang ZHAO, Bingxu LI, Shenglei LI, Xiaotao DONG, Ling YUAN
Published: (2022-09-01)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
by: Hongfu Cai, et al.
Published: (2021-11-01)